Ningbo Inno Pharmchem Co., Ltd. discusses how 4-Bromo-3,5-dimethylisoxazole (CAS 10558-25-5) is a vital pharmaceutical intermediate for developing GPR40 agonists and compounds with in vivo hypoglycemic activity.
